Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT
Thomas A. McFarland, MD close
bfvxvTKivB0
Thomas A. McFarland, MD
 

Thomas A. McFarland, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McFarland is a Clinical Professor of Medicine at the University of Wisconsin-Madison and is the Director of the UW combined Hematology/Oncology Fellowship program. He was the former Medical Director of the UW Carbone Cancer Center at 1 S. Park. Dr. McFarland holds a long tradition of teaching and developed the fellows' clinical rotation at the 1 South Park UWCCC. He has participated in the fellowship program for many years as a teacher and also served on many committees, prior to being appointed the Director. 

 
Dr. McFarland holds certifications from the American Board of Internal Medicine in Internal Medicine, Oncology and Hematology. His clinical interests in oncology include the treatment and diagnosis of sarcomas and melanoma, in addition to all general oncologic illnesses. His interests in hematology include the treatment and diagnosis of lymphomas and acute and chronic leukemias. He treats all general hematologic malignancies and non-malignant hematologic illnesses as well. Dr. McFarland is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group.

Specialties

Hematology

Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Other Locations

Beaver Dam Community Hospital (Beaver Dam)
(920) 887-4105  | (888) 703-2778 |  Map

Hospital Affiliation(s)

Meriter Hospital (primary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Medical Oncology
Fellowship Tufts-New England Medical Center, Boston, MA
Residency Tufts-New England Medical Center, Boston, MA
Internship Tufts-New England Medical Center, Boston, MA
Medical School University of Illinois College of Medicine, Champaign-Urbana, IL, 1987

Procedures

Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Research

Dr. McFarland actively participates in hematology and oncology clinical trials.


PubMed Articles
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G . A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS . VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS . Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G . Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
Morgan-Meadows S Mulkerin D Berlin JD Kim K Bailey H Saphner T Jumonville A Hansen R Ahuja H McFarland T Thomas JP . A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 2005;69(2):130-4
[PubMed ID: 16118509]